Skip to main content
. 2022 Mar 30;298(5):101885. doi: 10.1016/j.jbc.2022.101885

Figure 5.

Figure 5

RNA-Seq analysis identifies EPO as a novel hCAR target gene. The total RNA from HepG2-hCAR was prepared 72 h after Dox (1 μg/ml) or vehicle control treatment for RNA-Seq analysis as detailed under the “Experimental procedures” section. A, the volcano plot of RNA-Seq data showed 374 upregulated and 348 downregulated genes in HepG2-hCAR cells after hCAR induction. B, heatmaps illustrate 10 selected upregulated and downregulated genes with high fold changes in HepG2-hCAR cells treated with Dox or vehicle control. RT–PCR validation of RNA-Seq analysis results for the 10 upregulated and 10 downregulated genes in HepG2-hCAR (C), Hep3B-hCAR (D), HepaRG WT and hCAR-KO cells (E), respectively. Data were collected from three independent experiments and expressed as mean ± SD in C–E. ∗p < 0.05 and ∗∗p < 0.01. Dox, doxycycline; EPO, erythropoietin; hCAR, human constitutive androstane receptor; ND, not detected.